2022
Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich MD, Shah NR, Taylor TH, Page ST, Schiller SJ, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach PA. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLOS ONE 2022, 17: e0263591. PMID: 35213547, PMCID: PMC8880885, DOI: 10.1371/journal.pone.0263591.Peer-Reviewed Original ResearchConceptsStandard of careSubcutaneous sarilumabMechanical ventilationSevere COVID-19 diseaseHospitalized COVID-19 patientsDays of randomizationIL-6R inhibitionRate of intubationTrial of patientsSevere COVID-19COVID-19 patientsNumber of patientsVA Medical CenterAnti-inflammatory drugsCOVID-19SARS-CoV-2COVID-19 diseaseData monitoring committeeEligible patientsPrimary endpointSOC armPrimary outcomeRespiratory compromiseElectronic health record systemsClinical criteria
2011
Environmental Cleaning Intervention and Risk of Acquiring Multidrug-Resistant Organisms From Prior Room Occupants
Datta R, Platt R, Yokoe DS, Huang SS. Environmental Cleaning Intervention and Risk of Acquiring Multidrug-Resistant Organisms From Prior Room Occupants. JAMA Internal Medicine 2011, 171: 491-494. PMID: 21444840, DOI: 10.1001/archinternmed.2011.64.Peer-Reviewed Original ResearchConceptsMethicillin-resistant Staphylococcus aureusRisk of acquisitionPrior room occupantsVancomycin-resistant enteroccociIntensive care unitCare unitIntervention periodAcquisition of MRSAIntensive care unit roomsRetrospective cohort studyMultidrug-resistant organismsAcademic medical centerEnvironmental cleaning interventionsVRE acquisitionEligible patientsMRSA carriersVRE transmissionCardiac surgeryCohort studyMRSA acquisitionNeurosurgery unitThoracic surgeryMedical CenterVRE carriersGeneral surgery